Company Website

Contact Information:

Rob Kim
(425) 802-9809
rkim@Immunomedics.com

Ann Dvorak
(612) 710-0429
advorak@immunomedics.com

Speak with the representatives during the times listed below via https://engage.veeva.com/m.html?j=7056759520&pwd=988955 (Link works for all times listed)
• 7:00am CT - 7:30am CT
• 9:45am CT - 10:15am CT
• 12:00pm CT - 1:00pm CT
• 3:45pm CT - 4:45pm CT 

Virtual Exhibit Hall Home

Immunomedics, a subsidiary of Gilead Sciences, is a leader in next generation antibody-drug conjugate (ADC) technology, committed to helping people with hard-to-treat cancers. Our proprietary ADC binds to Trop-2-expressing cancer cells and is internalized with the subsequent release of SN-38 via hydrolysis of the linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. For more information, visit: www.immunomedics.com.